Tài liệu Báo cáo y học: "Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for

Diabetes mellitus is characterized by reduced insulin secretion from pancreatic β-cells (type 1 diabetes) [1] or deficient insulin action (type 2 diabetes) [2], both causing an increase in blood glucose concentration. High blood glucose (hyperglycemia) represents the main pathogenic factor for the development of diabetic complications including coronary heart disease, retinopathy, nephropathy, and neuropathy [3, 4]. In addition, chronic hyperglycemia leads to progressive impairment of insulin secretion and to insulin resistance of peripheral tissues (referred to as glucose toxicity) [1, 2, 5, 6]. As a consequence, the treatment of diabetes has been mainly focused on maintaining normal blood glucose levels. For that purpose either insulin or hypoglycemic agents have been used as standard therapeutic agents for the treatment of diabetes [7]. The mechanism of action of the antidiabetic agents used for the treatment of type 2 diabetes, include increasing insulin release, improving glucose disposal, controlling hepatic glucose release or inhibiting intestinal glucose absorption [8]